FROST PHILLIP MD ET AL purchased $71K of COCP (indirect holdings)
FROST PHILLIP MD ET AL purchased 75,000 indirectly-held shares of Cocrystal Pharma, Inc. (COCP) at $0.94 on 2026-08-03.
How this was made
The 30-second read
Why it matters
The only new fact is the reported open-market purchase amount, price, and post-transaction holdings; it does not include guidance, trial results, financing, or regulatory updates.
Market read
Traders may note the insider buy as a small sentiment input, but it is unlikely to drive repricing without additional catalysts.
What to watch
The filing does not state intent, timing rationale, or whether other insiders are buying; without a 10b5-1 plan, it still may be routine compensation-related or opportunistic.
Background
This is an SEC Form 4 insider transaction disclosure for Cocrystal Pharma, Inc.
Ticker impact
Cocrystal Pharma disclosed a Form 4 open-market purchase of 75,000 shares by a director/10% owner on 2026-08-03.
Likely limited, short-lived sentiment lift unless follow-on buying or operational catalysts emerge.
Form 4 insider purchases can support sentiment, but this transaction is small relative to typical liquidity and provides no new company-specific operating or financial information.
Market effects
No clear sector read-through from a single small insider purchase at a micro/small-cap biotech.
None indicated.
None indicated.
Counterpoint
Insider buying in Form 4s is often discretionary and may not reflect a durable change in fundamentals, especially without accompanying operational news.
Key entities
- issuerCocrystal Pharma, Inc.
COCP, subject of the Form 4 insider transaction disclosure.
- insiderFROST PHILLIP MD ET AL
Director and 10% owner who reported an indirect open-market purchase.